PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1544759
PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1544759
Self-monitoring Blood Glucose Devices Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032
The Self-monitoring Blood Glucose Devices Market size will grow at an 11.6% CAGR during 2024-2032, driven by the increasing prevalence of Type 1 diabetes. According to WHO, approximately 422 million people globally are living with diabetes, with the majority residing in low- and middle-income countries. Each year, diabetes directly accounts for 1.5 million deaths worldwide. Type 1 diabetes requires continuous monitoring of blood glucose levels, necessitating the use of reliable SMBG devices. The wider awareness about the condition and its early diagnosis is driving advancements in SMBG technology, leading to the development of more accurate, user-friendly, and innovative devices.
Modern SMBG devices offer higher precision in blood glucose measurements, reducing errors and ensuring reliable data for effective diabetes management. User-friendly designs, including simple interfaces, minimal blood sample requirements, and rapid result display, are making these devices more accessible to a broader range of users, including the elderly and those with limited technical skills. Additionally, advancements such as automated data logging, integration with mobile apps, and voice-guided instructions are further simplifying the monitoring process, enhancing patient compliance and overall satisfaction.
The self-monitoring blood glucose devices industry is classified based on product, application, end-use, and region.
The type 1 diabetes segment will grow rapidly through 2032, as it necessitates continuous monitoring of blood glucose levels. Self-monitoring blood glucose (SMBG) devices, such as glucometers, test strips, and lancets, have become essential tools for individuals with Type 1 diabetes to manage their condition effectively. Enhanced accuracy, ease of use, and integration with digital health platforms are among the key factors contributing to the widespread adoption of these devices among Type 1 diabetes patients.
The home care segment will witness steady growth through 2032. Home care offers a convenient and cost-effective alternative to hospital visits, allowing patients to monitor their blood glucose levels in the comfort of their homes. The integration of SMBG devices with smartphones and telehealth platforms further facilitates remote monitoring and consultation, enhancing patient compliance and overall disease management.
Europe self-Monitoring blood glucose devices industry will significantly over 2024-2032, driven by a combination of high diabetes prevalence, favorable healthcare policies, and technological advancements. The European healthcare system's emphasis on preventive care and chronic disease management supports the widespread use of self-monitoring devices. Additionally, government initiatives and reimbursement policies aimed at reducing the burden of diabetes are encouraging the adoption of SMBG devices across Europe.
Table of Contents
Chapter 1 Methodology and Scope
- 1.1 Market scope and definitions
- 1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
- 1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
- 1.4 Forecast model
- 1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources
Chapter 2 Executive Summary
- 2.1 Industry 360° synopsis
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Rising prevalence of diabetes worldwide
- 3.2.1.2 Technological advancements in developed countries
- 3.2.1.3 Government initiatives for increasing awareness among people
- 3.2.2 Industry pitfalls and challenges
- 3.2.2.1 High cost of advanced devices and accessories in developing countries
- 3.2.2.2 Lack of reimbursement and stringent regulations for SMBG devices
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Regulatory landscape
- 3.5 Technological landscape
- 3.6 Future market trends
- 3.7 Porter's analysis
- 3.8 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
- 4.1 Introduction
- 4.2 Company market share analysis
- 4.3 Company matrix analysis
- 4.4 Competitive analysis of major market players
- 4.5 Competitive positioning matrix
- 4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Product, 2018 - 2032 ($ Mn)
- 5.1 Key trends
- 5.2 Self-monitoring blood glucose meters
- 5.3 Consumables
- 5.3.1 Testing strips
- 5.3.2 Lancets
Chapter 6 Market Estimates and Forecast, By Application, 2018 - 2032 ($ Mn)
- 6.1 Key trends
- 6.2 Type 1 diabetes
- 6.3 Type 2 diabetes
- 6.4 Gestational diabetes
Chapter 7 Market Estimates and Forecast, By End-use, 2018 - 2032 ($ Mn)
- 7.1 Key trends
- 7.2 Hospitals
- 7.3 Ambulatory surgery centers
- 7.4 Diagnostic centers
- 7.5 Home care
- 7.6 Other end-users
Chapter 8 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)
- 8.1 Key trends
- 8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Netherlands
- 8.3.7 Rest of Europe
- 8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
- 8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
- 8.5.4 Rest of Latin America
- 8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE
- 8.6.4 Rest of Middle East and Africa
Chapter 9 Company Profiles
- 9.1 Abbott Laboratories
- 9.2 AgaMatrix
- 9.3 All Medicus Co., Ltd.
- 9.4 Arkray, Inc.
- 9.5 Ascensia Diabetes Care Holdings AG
- 9.6 B. Braun Melsungen AG
- 9.7 Bionime Corporation
- 9.8 DarioHealth Corp.
- 9.9 Dexcom, Inc.
- 9.10 Essenlife Bioscience, Inc.
- 9.11 F. Hoffmann-La Roche Ltd.
- 9.12 LifeScan Inc.
- 9.13 Medtronic plc
- 9.14 Nova Biomedical, Inc.
- 9.15 Sinocare Inc.
